Tregs have been demonstrated to inhibit NK cells from gastrointestinal stromal tumors (GIST) by competing for IL-2 availability and secrete IL-4, indoleamine-2,3-dioxygenase (IDO). This evidence concerns the gene IDO2 and gastrointestinal stromal tumor.